Sagar Stephen M
McMaster University and Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.
Integr Cancer Ther. 2007 Jun;6(2):166-73. doi: 10.1177/1534735407301566.
Silymarin (Silybum marianum [L.] Gaertn. [Asteraceae]) is a promising agent for cancer prevention, adjuvant cancer treatment, and reduction of iatrogenic toxicity. Although it is safe and free of serious adverse side effects, few studies have evaluated its use alongside conventional cytotoxic therapies, and adverse events associated with long-term administration are uncertain. Although it may prevent some types of cancer, its promotion of tissue regeneration and its potential estrogen activity could promote the growth of some tumors. Further clinical trials using authenticated fractions of silymarin as simple and complex derivatives are required prior to any general recommendations. Future research should focus on authentication of active chemicals, pharmacokinetics, adverse interactions and quality control, prevention of cancer initiation and progression, adjuvant therapy for specific cancers, and prevention of toxicity from anticancer therapies.
水飞蓟素（水飞蓟 [L.] 盖尔特恩 [菊科]）是一种有前景的用于癌症预防、辅助癌症治疗以及降低医源性毒性的药物。尽管它安全且无严重不良副作用，但很少有研究评估其与传统细胞毒性疗法联合使用的情况，并且与长期给药相关的不良事件尚不确定。虽然它可能预防某些类型的癌症，但其促进组织再生的作用及其潜在的雌激素活性可能会促进某些肿瘤的生长。在给出任何一般性建议之前，需要进一步使用经过认证的水飞蓟素馏分作为简单和复杂衍生物进行临床试验。未来的研究应集中在活性化学物质的鉴定、药代动力学、不良相互作用和质量控制、癌症起始和进展的预防、特定癌症的辅助治疗以及抗癌疗法毒性的预防上。
